Company performance
Current Price
as of Jan 17, 2025$0.00
P/E Ratio
N/A
Market Cap
$10.63K
- PVT
Description
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
Metrics
Overview
- HQModi’in, JM
- SectorHealth Technology
- IndustryBiotechnology
- TickerVBLT
- Price$0.0011+10.00%
Trading Information
- Market cap$0.01M
- Float53.65%
- Average Daily Volume (1m)30,510
- Average Daily Volume (3m)109,742
- EPS-$14.58
Company
- Revenue$0.66M
- Rev growth (1yr)N/A
- Net income-$5.22M
- Gross margin-3,100.00%
- EBITDA margin-265,800.00%
- EBITDA-$5.32M
- EV$3.65M
- EV/Revenue5.54
- P/EN/A
- P/SN/A
- P/B0.00
Documents
SEC Filings